WIPF1

Across TCGA pan-cancer cohorts, WIPF1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of WIPF1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where WIPF1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types WIPF1 is over-expressed in tumor, although a few such as LSCC and COAD show the opposite, repressed pattern.

CCRCC, HNSC, and LSCC are the cancer types where WIPF1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in WIPF1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.621	<.001	11	view →
HNSC	Male	All	+0.468	<.001	8	view →
LSCC	Male	II,III,IV	−0.209	<.001	6	view →
COAD	All	All	−0.147	<.001	6	view →
PDAC	Female	All	+0.666	<.001	5	view →
LUAD	All	II,III,IV	−0.122	.005	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

WIPF1–CCRCC

Open the CCRCC breakdown →